dc.contributor.author | Pratt, G | |
dc.contributor.author | Yap, C | |
dc.contributor.author | Oldreive, C | |
dc.contributor.author | Slade, D | |
dc.contributor.author | Bishop, R | |
dc.contributor.author | Griffiths, M | |
dc.contributor.author | Dyer, MJS | |
dc.contributor.author | Fegan, C | |
dc.contributor.author | Oscier, D | |
dc.contributor.author | Pettitt, A | |
dc.contributor.author | Matutes, E | |
dc.contributor.author | Devereux, S | |
dc.contributor.author | Allsup, D | |
dc.contributor.author | Bloor, A | |
dc.contributor.author | Hillmen, P | |
dc.contributor.author | Follows, G | |
dc.contributor.author | Rule, S | |
dc.contributor.author | Moss, P | |
dc.contributor.author | Stankovic, T | |
dc.date.accessioned | 2018-03-02T14:58:37Z | |
dc.date.issued | 2018-08 | |
dc.identifier.citation | British journal of haematology, 2018, 182 (3), pp. 429 - 433 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1518 | |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.doi | 10.1111/bjh.14793 | |
dc.format | Print-Electronic | |
dc.format.extent | 429 - 433 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Humans | |
dc.subject | Lymphoma, Mantle-Cell | |
dc.subject | Lymphoproliferative Disorders | |
dc.subject | DNA Damage | |
dc.subject | Recurrence | |
dc.subject | Piperazines | |
dc.subject | Phthalazines | |
dc.subject | Survival Analysis | |
dc.subject | Maximum Tolerated Dose | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Tumor Suppressor Protein p53 | |
dc.subject | Leukemia, Lymphocytic, Chronic, B-Cell | |
dc.subject | Leukemia, Prolymphocytic, T-Cell | |
dc.subject | Ataxia Telangiectasia Mutated Proteins | |
dc.subject | Poly(ADP-ribose) Polymerase Inhibitors | |
dc.title | A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1111/bjh.14793 | |
rioxxterms.licenseref.startdate | 2018-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of haematology | |
pubs.issue | 3 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 182 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | en_US |
dc.contributor.icrauthor | Marsden, | |
dc.contributor.icrauthor | Yap, Christina | |